GUT3D-PLATE
Financiado
Ready to use cell culture plates for gut 3D models
3D cell culture models are considered the next-generation in vitro models. Several efforts are being devoted to better mimic human physiology and predict drug efficacy. In case of the intestinal tissue models, the 3D architecture...
3D cell culture models are considered the next-generation in vitro models. Several efforts are being devoted to better mimic human physiology and predict drug efficacy. In case of the intestinal tissue models, the 3D architecture of the intestinal tissue and the soft mechanical properties have been identified as key factors to obtain models with improved predictive capacities. However, there is a lack of low-cost and ease-to-use intestinal tissue models that encompass both elements. In the COMIET ERC project, we developed 3D cell culture scaffolds that accurately mimic the villus and crypt morphologies of the human intestine using soft materials. We used an innovative light-based approach to fabricate hydrogel scaffolds with the proper dimensions and mechanical properties of the tissue, in a reproducible manner. This ERC PoC GUT3D-PLATE will develop further the technology and customize a 3D low cost printing device to be able to fabricate ready-to-commercialize 3D cell culture substrates mimicking the intestinal physiology. These substrates will be provided as ready-to-use cell culture inserts, compatible with conventional assays and without the need of specialized equipment. The scaffolds support the growth of conventional intestinal cell lines and primary-derived cells and can be used as platforms for drug screening, disease modeling and microbiome interactions.
GUT3D-PLATE will also explore the commercial feasibility of the product by protecting the IPR, analyzing the market, and designing a business plan that provides the roadmap to attract investors. The intestinal 3D culture models will be attractive not only to the biomedical research community, but also to the pharma industry and CROs as they are increasingly investing in tools that better predict drug treatment efficacy and toxicity at early stages of the drug development process. This will reduce significantly the need for animal models and the overall cost, generating a major societal benefit.
ver más
Duración del proyecto: 27 meses
Fecha Inicio: 2020-03-09
Fecha Fin: 2022-06-30
Fecha Fin: 2022-06-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2022-06-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2019-POC:
ERC Proof of Concept Grant
Cerrada
hace 5 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUN...
Otra investigación y desarrollo experimental en ciencias naturales y técnicas asociacion
Perfil tecnológico
TRL
4-5
50K
Perfil tecnológico
TRL
4-5
50K